Newman Dignan & Sheerar Inc’s Ovid Therapeutics OVID Stock Holding History

Newman Dignan & Sheerar Inc’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-16,522	Closed	-$5.45K	–	191
2025 Q2	$5.45K	Hold	16,522	–	–	﹤0.01%	195
2025 Q1	$5.15K	Hold	16,522	–	–	﹤0.01%	176
2024 Q4	$15.4K	Hold	16,522	–	–	﹤0.01%	180
2024 Q3	$19.3K	Buy	+16,522	New	+$17.3K	﹤0.01%	186
2024 Q1	–	Sell	-16,522	Closed	-$53.2K	–	180
2023 Q4	$53.2K	Buy	+16,522	New	+$56.5K	0.02%	171
2023 Q3	–	Sell	-16,522	Closed	-$54.2K	–	177
2023 Q2	$54.2K	Buy	16,522 +1,000	+6%	+$3.4K	0.02%	180
2023 Q1	$40K	Hold	15,522	–	–	0.01%	188
2022 Q4	$28.9K	Hold	15,522	–	–	0.01%	187
2022 Q3	$29	Buy	+15,522	New	+$32.5K	﹤0.01%	178
2022 Q2	–	Sell	-15,522	Closed	-$49	–	196
2022 Q1	$49	Hold	15,522	–	–	0.01%	191
2021 Q4	$50K	Hold	15,522	–	–	0.02%	197
2021 Q3	$52K	Buy	+15,522	New	+$56.6K	0.02%	187
2021 Q2	–	Sell	-18,522	Closed	-$74K	–	190
2021 Q1	$74K	Buy	+18,522	New	+$61.5K	0.03%	176

Other funds holding OVID

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Newman Dignan & Sheerar Inc's OVID Position: Q3 2025 in Review

Newman Dignan & Sheerar Inc sold out of Ovid Therapeutics (OVID) in Q3 2025, closing a stake of 16,522 shares — an estimated $5.45K sold.

Newman Dignan & Sheerar Inc first reported a position in OVID in Q1 2021 and held it in 13 quarters. The position peaked at $74K in Q1 2021. 81 funds tracked by Wall St. Rank hold OVID as of Q3 2025.

Newman Dignan & Sheerar Inc reported no remaining Ovid Therapeutics position as of Q3 2025 after selling out during the quarter.
Newman Dignan & Sheerar Inc sold 16,522 Ovid Therapeutics shares in Q3 2025, an estimated $5.45K.
Newman Dignan & Sheerar Inc first reported a position in Ovid Therapeutics in Q1 2021 and held it in 13 quarters.
Newman Dignan & Sheerar Inc's Ovid Therapeutics position peaked at $74K in Q1 2021.
81 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2025.

Based on Newman Dignan & Sheerar Inc's 13F filing for Q3 2025, filed 9 Oct 2025.